A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants

Inclusion criteria

• Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests, and cardiac monitoring.
• Body mass index within the range 18.0 to 29.9 kg/m\^2 (inclusive) at screening visit.
• Male or female (Women of Non-Childbearing Potential \[WONCBP\]) Contraceptive use by participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants: Participants are eligible to participate if they agree to the following during the study intervention period up to at least 1 day after end of infusion of study intervention to ensure sufficient elimination of BAY3389934 (5 times the elimination half-life of BAY3389934 is approximately 5 hours):
• Refrain from donating sperm PLUS, either:
• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
• Must agree to use contraception /barrier as detailed below:
• Agree to use a male condom with female partner use of an additional highly effective contraceptive method with a failure rate of \< 1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant
• Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person Female participants: A female participant is eligible to participate if she is a WONCBP.
• A WONCBP must have a negative highly sensitive pregnancy test (serum) within 24 hours before the first dose of study intervention,
• The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
• Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

• Medical disorder, condition or history of such that would impair the participant's ability to take part in or complete this study in the opinion of the investigator.
• Diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention(s) will not be normal.
• Known hypersensitivity to any study intervention (active substances or excipients of the preparations) to be used in the study - including e.g. non-investigational medicinal products, challenge agents, or rescue medication.
• Known severe allergies, e.g. allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with corticosteroids, urticaria or significant non-allergic drug reactions.
• Aspirin hypersensitivity/ allergy.
• Febrile illness within 2 weeks before the start of the first study intervention.
• Known or suspected liver disorders and bile secretion/flow (cholestasis, also history of it).
• History of Morbus Meulengracht (Gilbert´s syndrome) or total bilirubin levels above ULN at screening.
• History of known or suspected malignant tumors.
• Tendency to develop keloids or major scars after injuries.
• Participants experienced surgery (6-months prior to first study intervention), or IM injection (2-week prior to first study intervention).
• Known disorders with increased bleeding risk (e.g., periodontosis, symptomatic hemorrhoids, acute gastritis, peptic ulcer, vascular malformations and also history of it).
• Known sensitivity to common causes of bleeding or bruises (e.g., nasal).
• Known congenital or acquired coagulation disorders (e.g. von Willebrand's disease, hemophilia, platelet dysfunction, etc.).